ArticleNeuropsychiatric disease and treatment2025
Efficacy of Magnetic Seizure Therapy in Patients with Schizophrenia and Combined fMRI-EEG to Explore the Regulatory Mechanisms of Brain Networks.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The diagnostic potential of unconjugated bilirubin in schizophrenia and bipolar disorder.BMC psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Magnetic Seizure Therapy (MST) is an emerging psychiatric physical therapy in recent years, and the MST technique induces seizures by stimulating the local cortex. Numerous studies have shown that compared to electroconvulsive therapy (ECT), magnetic shock therapy (MST) has relatively little effect on cognitive function, and thus has certain advantages in clinical application. However, as far as magnetic shock therapy itself is concerned, there are few studies specifically focusing on its efficacy in depth, and the mechanism of MST in treating schizophrenia is still unclear. Methods: This study centered on the key question of "the efficacy of magnetic stunning therapy for patients with schizophrenia and the combined fMRI-EEG to explore the regulatory mechanisms of brain networks". The study protocol describes our interventional clinical trial aimed at developing magnetic convulsive therapy as an effective and safe treatment for SCZ. The study population consisted of SCZ patients and healthy controls (Hc). Clinical symptoms, cognitive function, EEG and fMRI data were collected from the patient group at baseline, post-treatment and follow-up phases. We systematically assessed the clinical features and cognitive functions of the patients, combined with EEG and fMRI indexes to explore the brain network connectivity abnormalities in SCZ patients, and jointly explored the neuroimaging mechanisms in SCZ patients. Conclusion: Positive results from this trial may have a direct and significant impact on patients with SCZ. Once the MST demonstrates significant antipsychotic efficacy with high perceived safety, it will have significant implications for clinical practice. Brain network abnormality may be one of the core pathological mechanisms of SCZ. Therefore, by combining neurophysiological imaging techniques to scientifically verify the abnormality of SCZ brain network, the elucidation of this issue can help to further reveal the pathological mechanism of SCZ and provide a scientific basis for the effective and precise treatment of the disease. Trial Registration: ChiCTR2000038361 Registered on September 21, 2020.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.